De Luna et al. concluded that using a supplementary insulin analog was comparable to human insulin for GDM in terms of the efficacy in achieving glycemic control and can be safely used as a viable treatment option without an increased risk of hypoglycemia. This evidence concerns the gene INS and Hypoglycemia.